Comparable outcome of stem cell transplant versus bortezomib-based consolidation in myeloma patients after major response to induction

References

• Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–20.
   PubMed Web of Science ®Google Scholar
• Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, Anderson K. Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol. 2012;9:135–43.
   PubMed Web of Science ®Google Scholar
• Moreau P, Avet-Loiseau H, Harousseau JL, Attal M. Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. J Clin Oncol. 2011;29:1898–906.
   PubMed Web of Science ®Google Scholar
• Laubach JP, Schlossman RL, Mitsiades CS, Anderson KC, Richardson PG. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. Expert Rev Hematol. 2011;4:51–60.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Beksac M, Bladé J, Boccadoro M, Cavenagh J, Cavo M, et al. Current multiple myeloma treatment strategies with novel agents: an European perspective. Oncologist. 2010;15:6–25.
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91–7.
   PubMed Web of Science ®Google Scholar
• Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. Medical Research Council Adult Leukaemia Working Party: high dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875–83.
   PubMed Web of Science ®Google Scholar
• Van de Velde HJK, Liu X, Chen G, Cakana A, Draedt W, Bayssas M. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica. 2007;92:1399–406.
   PubMed Web of Science ®Google Scholar
• Lahuerta JJ, Mateos MV, Martinez-Lopez J, Rosiñol L, Sureda A, de la Rubia J, et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol. 2008;26:5775–82.
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Moreau P. Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med. 2009;360:2645–54.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rajkumar SV. Treatment of newly diagnosed myeloma. Leukemia. 2009;23:449–56.
   PubMed Web of Science ®Google Scholar
• Bensinger W. Stem-cell transplantatin for multiple myeloma in the era of novel drugs. J Clin Oncol. 2008;26:480–92.
   PubMed Web of Science ®Google Scholar
• Kumar S. Multiple myeloma – current issues and controversies. Cancer Treat Rev. 2010;36( Suppl 2):S3–11.
   PubMed Web of Science ®Google Scholar
• Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Bladé J, et al. International Myeloma Working Group: International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011;117:6063–73.
   PubMed Web of Science ®Google Scholar
• Engelhardt M, Kleber M, Udi J, Wäsch R, Spencer A, Patriarca F, et al. Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. Leuk Lymphoma. 2010;51:1424–43.
   PubMed Web of Science ®Google Scholar
• Bladé J, Rosiñol L, Sureda A, Ribera JM, Díaz-Mediavilla J, García-Laraña J, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood. 2005;106:3755–9.
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol. 2010;28:4621–9.
   PubMed Web of Science ®Google Scholar
• Popat R, Oakervee HE, Hallam S, Curry N, Odeh L, Foot N, et al. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. Br J Haematol. 2008;141:512–6.
   PubMed Web of Science ®Google Scholar
• Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005;129:755–62.
   PubMed Web of Science ®Google Scholar
• Kaufman JL, Nooka A, Vrana M, Gleason C, Heffner LT, Lonial S. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study. Cancer. 2010;116:3143–51.
   PubMed Web of Science ®Google Scholar
• Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C, et al. Brtezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood. 2011;118:5752–8.
   PubMed Web of Science ®Google Scholar
• Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012;120:9–12.
   PubMed Web of Science ®Google Scholar